BLUEJAY DIAGNOSTICS INC (BJDX)
US0956334009 - Common Stock
We assign a fundamental rating of 2 out of 10 to BJDX. BJDX was compared to 188 industry peers in the Health Care Equipment & Supplies industry. BJDX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BJDX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year BJDX has reported negative net income.
BJDX had a negative operating cash flow in the past year.
BJDX had negative earnings in each of the past 5 years.
In the past 5 years BJDX always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of BJDX (-204.43%) is worse than 91.98% of its industry peers.
Looking at the Return On Equity, with a value of -343.81%, BJDX is doing worse than 85.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -204.43% | ||
| ROE | -343.81% | ||
| ROIC | N/A |
ROA(3y)-96.61%
ROA(5y)-91.06%
ROE(3y)-147.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BJDX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BJDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BJDX has less shares outstanding than it did 1 year ago.
BJDX has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 14.22 indicates that BJDX is not in any danger for bankruptcy at the moment.
BJDX has a Altman-Z score of 14.22. This is amongst the best in the industry. BJDX outperforms 89.30% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that BJDX is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.00, BJDX is doing good in the industry, outperforming 65.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 14.22 |
ROIC/WACCN/A
WACC9.07%
2.3 Liquidity
BJDX has a Current Ratio of 1.82. This is a normal value and indicates that BJDX is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.82, BJDX is not doing good in the industry: 72.19% of the companies in the same industry are doing better.
A Quick Ratio of 1.82 indicates that BJDX should not have too much problems paying its short term obligations.
The Quick ratio of BJDX (1.82) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.82 |
3. Growth
3.1 Past
BJDX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.30%.
Looking at the last year, BJDX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)3.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.5%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, BJDX will show a very strong growth in Earnings Per Share. The EPS will grow by 25.91% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y98.61%
EPS Next 2Y41.26%
EPS Next 3Y25.91%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
BJDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BJDX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as BJDX's earnings are expected to grow with 25.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.26%
EPS Next 3Y25.91%
5. Dividend
5.1 Amount
BJDX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BLUEJAY DIAGNOSTICS INC
NASDAQ:BJDX (11/22/2024, 8:26:08 PM)
After market: 3.68 +0.16 (+4.55%)3.52
+0.02 (+0.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.94M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -204.43% | ||
| ROE | -343.81% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.82 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)3.3%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y98.61%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y